The Europe sarcopenia treatment market was valued at US$ 993.46 million in 2022 and is expected to reach US$ 1.46 billion by 2030; it is estimated to register a CAGR of 5.0% from 2022 to 2030.
Germany is an attractive market due to its innovative approach toward healthcare. According to the Federal Statistical Office, health expenditure in this country amounted to US$ 474 billion in 2021. The awareness of sarcopenia and sarcopenic obesity (SO) is gradually increasing in aging societies across Germany. Sarcopenia and SO are comparatively uncommon (< 5%) among German men aged 70 and above. Therefore, an upsurge in the cases of orthopedic disorders, coupled with the rising demand for nutritional supplements, drives the growth of the sarcopenia treatment market in Germany.
Rise in Malnutrition and Vitamin Deficiency Among Adults Boosts Europe Sarcopenia Treatment Market
Malnutrition is one of the major risk factors for sarcopenia. According to the WHO, approximately 2.3 billion adults worldwide were undernourished as of 2021, representing nearly 30% of the global population. Among the reported risk factors, protein-energy deficiency is a frequent cause of sarcopenia. Further, vitamin D deficiency or insufficiency is positively associated with an increased risk of multiple illnesses, such as cancer, obesity, cardiovascular disease, and sarcopenia. According to the National Institutes of Health (NIH), nearly 50% of the world's population suffers from vitamin D insufficiency, and ~1 billion people are vitamin D deficient.Europe Sarcopenia Treatment Market Overview
The sarcopenia treatment market in Europe is segmented into Germany, France, the UK, Italy, Spain, and the Rest of Europe. Europe occupies a significant position in the global sarcopenia treatment market and is estimated to register a notable CAGR during the forecast period.Germany is an attractive market due to its innovative approach toward healthcare. According to the Federal Statistical Office, health expenditure in this country amounted to US$ 474 billion in 2021. The awareness of sarcopenia and sarcopenic obesity (SO) is gradually increasing in aging societies across Germany. Sarcopenia and SO are comparatively uncommon (< 5%) among German men aged 70 and above. Therefore, an upsurge in the cases of orthopedic disorders, coupled with the rising demand for nutritional supplements, drives the growth of the sarcopenia treatment market in Germany.
Europe Sarcopenia Treatment Market Segmentation
The Europe sarcopenia treatment market is categorized into treatment type, distribution channel, and country.- Based on treatment type, the Europe sarcopenia treatment market is segmented into vitamin D and calcium supplement, protein supplement, vitamin B12 supplement, and others. The vitamin D and calcium supplement segment held the largest Europe sarcopenia treatment market share in 2022.
- In terms of distribution channel, the Europe sarcopenia treatment market is segmented into pharmacies, retail channels, online channels, and others. The pharmacies segment held the largest Europe sarcopenia treatment market share in 2022.
- By country, the Europe sarcopenia treatment market is segmented into Germany, France, Italy, the UK, Spain, and the Rest of Europe. Germany dominated the Europe sarcopenia treatment market share in 2022.
Table of Contents
1. Introduction
2. Executive Summary
3. Research Methodology
4. Europe Sarcopenia Treatment Market - Key Industry Dynamics
5. Sarcopenia Treatment Market - Europe Market Analysis
6. Europe Sarcopenia Treatment Market Analysis - By Treatment Type
7. Europe Sarcopenia Treatment Market Analysis - By Distribution Channel
8. Europe Sarcopenia Treatment Market - Country Analysis
9. Sarcopenia Treatment Market-Industry Landscape
10. Company Profiles
11. Appendix
Companies Mentioned
- Abbott Laboratories
- Amway Corp
- Bayer AG
- GSK Plc
- Metagenics LLC
- Nestle Health Science SA
- Novartis AG
- Pfizer Inc
- Sanofi SA
